Oral semaglutide reduced risk for cardiovascular events in people with type 2 diabetes, atherosclerotic CVD and kidney disease. It is now the first and only oral GLP-1 receptor agonist with proven ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

The researchers tracked nearly 175,000 patients with diabetes who received semaglutide - the active ingredient in Ozempic and other Novo products - and the same number of patients with diabetes ...

Oral semaglutide (Rybelsus; Novo Nordisk) taken once daily cut the risk of cardiovascular mortality, nonfatal MI, or nonfatal stroke in the trial by 14% after a mean follow-up of 47.5 months, a ...

Oral semaglutide reduced major cardiovascular events by 14% in patients with type 2 diabetes over nearly 4 years. The trial involved 9650 patients with type 2 diabetes and cardiovascular or kidney ...

The side effects of Ozempic (semaglutide) can include abdominal (belly) pain, diarrhea, nausea, and vomiting, among other digestive-related problems. Ozempic is not a high-risk medication for most ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...